Pelka K, Stec‐Polak M, Wojas‐Pelc A, et al. - Since the prevalence of antimitochondrial antibodies (AMA) and autoimmune liver diseases in subacute cutaneous lupus erythematosus (SCLE) patients has not been determined, researchers sought to evaluate the seropositivity rates for antimitochondrial M2 antibodies (AMA-M2) and autoantibodies correlated with autoimmune hepatitis in patients with newly diagnosed SCLE and to determine the coexistence and risk of development of autoimmune liver disease in such patients within 1 year of follow‐up. Data were analyzed from 33 patients with newly diagnosed SCLE. According to results, AMA‐M2 was observed in 20% of SCLE patients. In patients with SCLE, a high prevalence of AMA‐M2 was found. Compared with patients without AMA, those with SCLE and AMA‐M2 had significantly higher values of cholestatic enzymes. Newly diagnosed SCLE patients should be screened for the presence of AMA and should be clinically followed up. In patients with SCLE and AMA, avoiding drugs with potential liver toxicity should be advised.